Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 2

3(42.9%)

Phase 3

1(14.3%)

7Total

Phase 1(3)

Phase 2(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07448922Phase 2Not Yet Recruiting

A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors

Role: lead

NCT06674694Phase 1Recruiting

The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.

Role: lead

NCT05906537Phase 1Active Not Recruiting

SKB410 for Injection in Solid Tumors

Role: lead

NCT07030790Phase 1Recruiting

A Phase I Clinical Study of a Single Dose of KLA480

Role: lead

NCT05351788Phase 2Recruiting

SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Role: lead

NCT05496426Phase 2Unknown

A Study of KL130008 in Adults With Severe Alopecia Areata

Role: lead

NCT03426371Phase 3Unknown

Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial

Role: lead

All 7 trials loaded